Last reviewed · How we verify
Gabren (PROGABIDE)
Gabren works by enhancing the activity of the neurotransmitter GABA, which helps to calm down excessive neuronal activity in the brain.
Gabren, also known as Progabide, is a small molecule drug that targets the GABA-A receptor, an anion channel. It is a progabide drug class, but its commercial status and approved indications are unknown. The drug has a bioavailability of 60%, but its half-life and generic manufacturers are not specified. As a result, its current owner and off-patent status are also unclear. Further research is needed to determine its clinical use and safety profile.
At a glance
| Generic name | PROGABIDE |
|---|---|
| Drug class | progabide |
| Target | GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Mechanism of action
Think of GABA like a brake pedal in a car. When GABA binds to its receptors, it helps to slow down the activity of neurons, which can help to reduce anxiety, seizures, and other conditions. Gabren increases the effectiveness of GABA, allowing it to bind more easily to its receptors and produce a calming effect.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gabren CI brief — competitive landscape report
- Gabren updates RSS · CI watch RSS